Overview

A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:
All

Summary

To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Miami

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Zidovudine

Criteria

Inclusion Criteria

Patients must have:

- HIV seropositivity by both ELISA and Western blot.

- Biopsy proven progressive multifocal leukoencephalopathy (PML).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Intolerant to interferon.

- Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis,
multiple sclerosis (MS), or neurosyphilis.

Patients with the following are excluded:

- Intolerant to interferon.

- Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis,
multiple sclerosis (MS), or neurosyphilis.

Prior Medication:

Excluded:

- Patients receiving interferon for other reasons.